Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 11, 2025 489 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EPCORE FL-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR 2023 ASCO Annual Meeting Research Round Up: Advances in Treating Gynecologic... August 17, 2023 Many Men with Penile Cancer Do Not Get Recommended Treatments, Study... March 22, 2018 FDA Approves Imlunestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... October 10, 2025 Adjuvant Chemotherapy Customisation Based on ERCC1 and TS mRNA Levels Does... October 6, 2021 Load more HOT NEWS TIL Densities Association with Disease-Free Survival Differs by Primary Tumour Sidedness... Bringing AI to the data: the future of privacy-compliant cancer research Experimental Medulloblastoma Treatment Gets a Boost with Nanoparticles Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced...
